Skip to main content

Table 1 Baseline patient characteristics in the unmatched and propensity score-matched groups

From: Antithrombin use and 28-day in-hospital mortality among severe-burn patients: an observational nationwide study

Variable Unmatched groups Matched groups
Control (n = 3071) Antithrombin (n = 152) Standardized differences (%) Control (n = 103) Antithrombin (n = 103) Standardized differences (%)
Age, years (SD) 56.2 (26.5) 62.7 (22.0) −27.0 63.6 (21.3) 61.6 (21.8) 9.2
Sex (male) 1887 (61.4) 97 (63.8) −4.9 66 (64.1) 68 (66.0) −4.1
Burn index, mean (SD) 21.7 (17.1) 40.5 (23.4) −91.8 38.5 (23.9) 37.1 (22.1) 6.0
Inhalation injury without mechanical ventilation 188 (6.1) 1 (0.7) 30.5 1 (1.0) 1 (1.0) 0.0
Mechanical ventilation 651 (21.2) 124 (81.6) −151.6 83 (80.6) 79 (76.7) 9.5
Charlson Comorbidity Index ≥ 1 409 (13.3) 11 (7.2) 20.1 8 (7.8) 7 (6.8) 3.7
Academic hospital 1097 (35.7) 108 (71.1) −75.7 67 (65.0) 69 (67.0) −4.1
Hospital volume, cases
 Low 1163 (37.9) 14 (9.2) 71.8 13 (12.6) 12 (11.7) 3.0
 Medium 942 (30.7) 59 (38.8) −17.2 44 (42.7) 38 (36.9) 11.9
 High 966 (31.5) 79 (52.0) −42.5 46 (44.7) 53 (51.5) −13.6
Consciousness level 0.0
 Alert 2230 (72.6) 62 (40.8) 67.8 40 (38.8) 45 (43.7) −9.9
 Delirium 459 (14.9) 38 (25.0) −25.3 34 (33.0) 27 (26.2) 14.9
 Somnolence 129 (4.2) 15 (9.9) −22.3 9 (8.7) 11 (10.7) −6.6
 Coma 253 (8.2) 37 (24.3) −44.7 20 (19.4) 20 (19.4) 0.0
Antibiotics use 1229 (40.0) 114 (75.0) −75.7 76 (73.8) 74 (71.8) 4.4
Catecholamines
 Dopamine use 233 (7.6) 44 (28.9) −57.5 31 (30.1) 27 (26.2) 8.6
 Dobutamine use 47 (1.5) 13 (8.6) −32.5 6 (5.8) 9 (8.7) −11.2
 Noradrenaline use 139 (4.5) 28 (18.4) −44.7 15 (14.6) 14 (13.6) 2.8
Escharotomy performed 130 (4.2) 23 (15.1) −37.5 16 (15.5) 18 (17.5) −5.2
Debridement performed 127 (4.1) 10 (6.6) −10.9 7 (6.8) 6 (5.8) 4.0
Red blood cell use 109 (3.5) 39 (25.7) −65.9 23 (22.3) 21 (20.4) 4.7
Fresh-frozen plasma use 217 (7.1) 81 (53.3) −116.5 44 (42.7) 45 (43.7) −2.0
Platelet use 19 (0.6) 15 (9.9) −42.4 5 (4.9) 4 (3.9) 4.8
Albumin use 608 (19.8) 133 (87.5) −184.9 89 (86.4) 87 (84.5) 5.5
Haptoglobin use 196 (6.4) 67 (44.1) −96.3 31 (30.1) 31 (30.1) 0.0
Heparin use 644 (21.0) 110 (72.4) −120.2 73 (70.9) 72 (69.9) 2.1
Thrombomodulin use 14 (0.5) 30 (19.7) −67.5 4 (3.9) 5 (4.9) −4.8
Gabexate mesilate use 25 (0.8) 15 (9.9) −41.1 5 (4.9) 6 (5.8) −4.3
Nafamostat mesilate use 57 (1.9) 19 (12.5) −42.1 16 (15.5) 16 (15.5) 0.0
Ulinastatin use 50 (1.6) 20 (13.2) −45.2 9 (8.7) 11 (10.7) −6.6
  1. SD standard deviation